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Abstract
Background: Colorectal cancer (CRC) is the fourth most frequently diagnosed cancer and the second leading cause
of neoplasm-related death in the United States. Several studies analyzed the efficacy of bevacizumab combined
with different chemotherapy regimens consisting on drugs such as 5-FU, capecitabine, irinotecan and oxaliplatin.
This systematic review aims to evaluate the effectiveness and safety of chemotherapy plus bevacizumab versus
chemotherapy alone in patients with previously untreated advanced or metastatic colorectal cancer (mCRC).
Methods: Several databases were searched, including MEDLINE, EMBASE, LILACS, and CENTRAL. The primary
endpoints were overall survival and progression-free survival. Data extracted from the studies were combined by
using hazard ratio (HR) or risk ratio (RR) with their corresponding 95 % confidence intervals (95 % CI).
Results: The final analysis included 9 trials comprising 3,914 patients. Patients who received the combined
treatment (chemotherapy + bevacizumab) had higher response rates (RR = 0.89; 95 % CI: 0.82 to 0.96; p = 0.003)
with heterogeneity, higher progression-free survival (HR = 0.69; 95 % CI: 0.63 to 0.75; p < 0.00001) and also higher
overall survival rates (HR = 0.87; 95 % CI: 0.80 to 0.95; p = 0.002) with moderate heterogeneity. Regarding adverse
events and severe toxicities (grade ≥ 3), the group receiving the combined therapy had higher rates of hypertension
(RR = 3.56 95 % CI: 2.58 to 4.92; p < 0.00001), proteinuria (RR = 1.89; 95 % CI: 1.26 to 2.84; p = 0.002), gastrointestinal
perforation (RR = 3.63; 95 % CI: 1.31 to 10.09; p = 0.01), any thromboembolic events (RR = 1.44; 95 % CI: 1.20 to
1.73; p = 0.0001), and bleeding (RR = 1.81; 95 % CI: 1.22 to 2.67; p = 0.003).
Conclusion: The combination of chemotherapy with bevacizumab increased the response rate, progression-free
survival and overall survival of patients with mCRC without prior chemotherapy. The results of progression-free
survival (PFS) and overall survival (OS) were comparatively higher in those subgroups of patients receiving bolus
5-FU or capecitabine-based chemotherapy plus bevacizumab, when compared to patients treated with infusional
%-FU plus bevacizumab (no difference in PFS and OS). Regarding the type of cytotoxic scheme, regimens containing
irinotecan and fluoropyrimidine monotherapy showed superior efficacy results when combined to bevacizumab.
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Background
Colorectal cancer (CRC) is the fourth most frequently
diagnosed cancer and the second leading cause of
neoplasm-related death in the United States [1, 2]. Thus,
CRC constitutes a public health problem that affects
men and women in similar proportion and is more
prevalent in Western countries [3].
Approximately 25 % of patients already have meta-
static disease at the moment of diagnosis and nearly
50 % will develop metastases [4, 5]. Over the past
10 years, various combinations of chemotherapy were
investigated for the treatment of metastatic colorectal
cancer (mCRC) [6].
Since its introduction by Heidelberger in 1957, 5-
fluorouracil (5-FU) has become one of the most exten-
sively used drugs in the treatment of mCRC worldwide
and also the backbone of nearly all the recommended
and researched chemotherapy associations [7–9]. Cape-
citabine, another oral fluoropyrimidine, is currently rec-
ommended as an alternative for the treatment of these
patients since its similar efficacy to 5-FU was demon-
strated in randomized studies [10]. Subsequently, two
other cytotoxic drugs (irinotecan and oxaliplatin) had
their efficacy confirmed in the treatment of mCRC,
thus becoming part of treatment protocols since 1999
[7, 11–13].
Lately, the eyes of the medical community around the
world have been turned to targeted molecular therapies.
In February 2004, the Food and Drug Administration
(FDA) approved bevacizumab - a recombinant human-
ized monoclonal antibody against vascular endothelial
growth factor (VEGF) - combined with standard chemo-
therapy to treat mCRC [14, 15]. Less than a year later,
the European Medicines Agency (EMEA) also gave the
drug its approval.
Several studies analyzed the efficacy of bevacizumab
combined with different chemotherapy regimens consist-
ing on drugs such as 5-FU, capecitabine, irinotecan and
oxaliplatin [16]. Four meta-analyses published between
2009 and 2012 compiled the results of randomized trials
on standard chemotherapy with bevacizumab in the
therapy of mCRC [16–19]. Results of these meta-
analyses evidenced the difference in overall survival fa-
voring the groups treated with chemotherapy plus beva-
cizumab. In 2014, another meta-analysis [20] showed
that the addition of bevacizumab to first-line chemother-
apy for mCRC did not achieve clinical benefit for overall
survival. This latter study brought out questions about
the real benefit of chemotherapy plus bevacizumab for
these patients. Since then, the availability of new clinical
studies produced uncertain or controversial results re-
garding the effectiveness of this treatment, particularly
for the endpoint of overall survival [21–24]. In this con-
text, we felt it was appropriate to re-assess the role of
bevacizumab as a component of first-line therapy in pa-
tients with advanced colorectal cancer.
This systematic review aims to evaluate the effective-
ness and safety of bevacizumab associated with standard





Randomized controlled clinical trials (RCTs) with parallel
design that compared the use of chemotherapy regimens
associated with bevacizumab against other regimens with-
out bevacizumab.
Types of participants
Patients aged ≥ 18 years old with cytological or histo-
logical diagnosis of mCRC without prior chemotherapy
(only in first-line treatment).
Search strategy for identification of studies
A wide search of the main computerized databases of
interest was conducted, including EMBASE, LILACS,
MEDLINE, SCI, CENTRAL, The National Cancer
Institute Clinical Trials service, and The Clinical Trials
Register. In addition, the abstracts published in the
proceedings of the American Society of Clinical
Oncology (ASCO), American Association for Cancer
Research (AACR), European Society for Medical
Oncology (ESMO) and World Congress on Gastro-
intestinal Cancer were also searched.
For MEDLINE, we used the search strategy method-
ology for randomized controlled trials [25] recom-
mended by the Cochrane Collaboration [26]. For
EMBASE, we used adaptations of this same strategy
[25], and for LILACS, we used the search strategy meth-
odology reported by Castro et al. [27]. We performed an
additional search on the SCI database looking for papers
that were cited on the included studies. We added the
specific terms pertinent to this review to the overall
search strategy methodology for each database.
The overall search strategy was: #1 “bevacizumab”
(Supplementary Concept) OR “bevacizumab” (All
Fields); 2# “colorectal neoplasms” (MeSH Terms) OR
“colorectal” (All Fields) AND “neoplasms” (All Fields)
OR “colorectal neoplasms” (All Fields) OR “colorectal”
(All Fields) AND “cancer” (All Fields) OR “colorectal
cancer” (All Fields); 3# Clinical Trial (ptyp).
Searches of electronic databases combined the
terms #1 AND #2 AND #3 and did not have lan-
guage or date restrictions.
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Critical evaluation of the selected studies
All the references retrieved by the search strategies had
their title and abstract evaluated by two of the re-
searchers. Every reference with the least indication of
fulfilling the inclusion criteria was listed as pre-selected.
We retrieved the complete article of all pre-selected
references. Two different researchers analyzed the arti-
cles and included or excluded them according to the
previously reported criteria. The excluded trials and the
reason for their exclusion are listed in this article. Data
was extracted from all the included trials.
Details regarding the main methodology characteristics
empirically linked to bias [28] were extracted with the
methodological validity of each selected trial assessed by
two reviewers (T.E.A.B and O.C). Particular attention
was given to some items such as: the generation and
concealment of the sequence of randomization, blinding,
application of intention-to-treat analysis, sample size
pre-definition, loss of follow-up description, adverse
events reports, if the trial was multicentric and the
source of sponsorship.
Data extraction
Two independent reviewers extracted the data. The
name of the first author and year of publication were
used to identify the study. All data were extracted dir-
ectly from the text or calculated from the available infor-
mation when necessary. The data of all trials were based
on the intention-to-treat principle, so they compared all
patients allocated in one treatment with all those allo-
cated in the other arm.
The primary endpoints were progression-free survival
(defined as time from randomization to either death or
disease progression, whichever occurred first) and over-
all survival. If data on progression-free survival were not
available, data on time to progression or event free sur-
vival were assessed.
Other clinical outcomes were evaluated: overall re-
sponse rate (complete response + partial response) and
the more frequently found adverse events (grade ≥ 3),
both hematological (anemia, neutropenia, febrile neutro-
penia and thrombocytopenia) and non-hematological
(diarrhea, hypertension, proteinuria, gastrointestinal per-
foration, nausea and vomiting and any thromboembolic
and bleeding events).
Analysis and presentation of results
Data were analyzed using the Review Manager 5.1.2 stat-
istical package (Cochrane Collaboration Software) [29].
Dichotomous clinical outcomes are reported as risk ra-
tio (RR) and survival data as hazard ratio (HR) [30]. The
corresponding 95 % confidence interval (95 % CI) was
calculated, considering P values less than 5 % (p < 0.05).
A statistic for measuring heterogeneity was calculated
through I2 method (25 % was considered low-level het-
erogeneity, 25–50 % moderate-level heterogeneity and
> 50 % high-level heterogeneity) [31, 32].
To estimate the absolute gains in progression-free sur-
vival and overall survival, we calculated the meta-
analytic survival curves as suggested by Parmar et al.
[30]. A pooled estimate of the HR was computed by a
fixed-effect model according to the inverse-variance
method [33]. Thus, for effectiveness or side effects an
HR or RR > 1 favors standard arm (control), whereas an
HR or RR < 1 favors bevacizumab treatment.
If statistical heterogeneity was found in the meta-
analysis, we performed an additional analysis using the
random-effects model described by DerSimonian and
Laird [34], that provides a more conservative analysis.
To assess the possibility of publication bias, we per-
formed the funnel plot test described by Egger et al.
[35]. When the pooled results were significant, the num-
ber of patients needed to treat (NNT or NNH) to cause
or to prevent one event was calculated by pooling abso-
lute risk differences in trials included in meta-analyses
[36–38]. For all analyses, a forest plot was generated to
display results.
In the efficacy assessment, a subgroup analysis was
planned to evaluate the influence of the type of fluoropyri-
midine (bolus or infusional 5-FU or capecitabine) and
cytotoxic agents used (only fluoropyrimidine monother-
apy, oxaliplatin-based and irinotecan-based regimens).
Results
The diagram represents the flow of identification and
inclusion of trials, as recommended by the Preferred
Reporting Items for Systematic reviews and Meta-
Analyses (PRISMA) statement [39] (Fig. 1).
In the first search, 228 references were identified and
screened. Nineteen were considered of potential interest
and selected for analysis in full. Of these, 10 were ex-
cluded for different reasons as described in Table 1. The
final analysis included 9 trials comprising 3,914 patients
(Table 2).
A comprehensive analysis was performed regarding
the presence of relevant biomarkers, such as VEGF-A
isoform or KRAS status, which might have predicted
superior efficacy for patients treated with bevacizumab
or other particular regimens. Three studies reported
separated data of efficacy for patients with wild type
(WD) or mutated (MT) KRAS. Mutation status KRAS
was determined for patients participating in the ITACA
trial [21, 23], also for 315 (66,9 %) of those on MAX
trial [22, 40, 41] and 230 patients (28.3 %) on the
AVF2107 study [14, 42, 43].
Quality assessments for eligible trials were evaluated
and performed by extracting key methodological
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characteristics from published trials (Additional file 1:
Table S1).
Characteristics and results of included studies
Studies containing chemotherapy (irinotecan-based) +
bevacizumab
Bevacizumab was associated with irinotecan in 3 random-
ized studies [14, 24, 42, 44].
AVF 2107 trial
This multicenter, placebo-controlled study [14] analyzed
patients with mCRC and measurable disease. Patients
were initially randomized 1:1:1 to 3 groups: placebo
combined with chemotherapy (IFL regimen: irinotecan
+ fluorouracil + leucovorin); bevacizumab (5 mg/kg)
every 15 days combined with chemotherapy (IFL regi-
men); and bevacizumab combined with 5-FU and
leucovorin (abandoned after the safety of bevacizumab
+ irinotecan was well established). Treatment continued
until progression of disease. The primary endpoint was
overall survival (Table 2). In the ITT analysis, 411 pa-
tients were randomized to the group IFL + placebo and
402 patients to the group IFL + bevacizumab.
The association of bevacizumab to the IFL regimen
significantly increased the objective response rate, com-
pared to IFL + placebo (44.8 % vs. 34.8 %; p = 0.004)
(Table 3). Progression-free survival (10.6 months vs.
6.2 months; p < 0.001) and overall survival (20.3 months
vs. 15.6 months; p < 0.001) were higher in the group re-
ceiving bevacizumab (Table 3).
The combination of IFL + bevacizumab was well tol-
erated. In general, toxicity levels ≥ 3 were higher in the
group treated with bevacizumab (84.9 % vs. 74 %; p <
0.01). There was no significant difference in the rate of
thromboembolic events, proteinuria, and bleeding or
gastrointestinal perforation. Hypertension (grade ≥ 3)
was more frequent in the group treated with bevacizu-
mab (11 % vs. 2.3 %; p <0.01) (Table 5).
ARTIST trial
This prospective, multicenter study [24] assessed patients
diagnosed with mCRC and measurable disease. The trial
included Chinese patients and randomized (2:1) 139 pa-
tients to receive bevacizumab (5 mg/kg every 15 days)
combined with chemotherapy (IFL regimen) and 64 pa-
tients to receive only IFL. The treatment continued until
progression of disease. Rate of progression-free survival at
6 months and duration of progression-free survival were
co-primary endpoints (Table 2).
The combination of IFL + bevacizumab significantly in-
creased the objective response rate, compared with IFL
alone (35.3 % vs. 17.2 %; p = 0.013) (Table 3). Progression-
free survival (8.3 months vs. 4.2 months; p < 0.001) and
overall survival (18.7 months vs. 13.4 months; p = 0.014)
Fig. 1 Trial selection flow
Table 1 Characteristics of excluded studies
Reasons for exclusion
Lee 2012 [72] Nonrandomized
(cost-effectiveness analysis)
Shiroiwa 2010 [73] Nonrandomized
(cost-effectiveness analysis)
Zhang 2012 [74] Nonrandomized
Allegra 2009/2011 [75, 76] Adjuvant treatment
Ducreux 2009 [77] Different comparison
(bevacizumab in both arms)
Pectasides 2012 [78] Different comparison
(bevacizumab in both arms)
Souglakos 2012 [79] Different comparison
(bevacizumab in both arms)
Díaz-Rubio 2012 [80] Different comparison
(bevacizumab in both arms)
Price 2012 [81] Subgroup analysis of another study
Moehler 2009 [82] Nonrandomized
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Table 2 Characteristics of randomized studies evaluating bevacizumab plus chemotherapy in patients with mCRC in first line
chemotherapy
Study n Type of study Patients Comparison Primary
endpoint
Regimens containing irinotecan with/without bevacizumab




mCRC, ECOG PS 0–1,
≥ 18 years
IFL/Bev (5 mg/kg) OS
IFL/placebo
Guan 2011 [24] (ARTIST) 203 Randomized, multicenter,
phase III
mCRC, ECOG PS 0–1,
≥ 18 years
IFL/Bev (5 mg/kg) PFS and PFS rate
in 6 months
IFL
Stathopoulos 2010 [44] 222 Randomized, phase III mCRC, ECOG PS 0–2,
≥ 18 years
IFL/Bev (7.5 mg/kg) OS
IFL





mCRC, ECOG PS 0–1,
≥ 18 years
XELOX or FOLFOX/Bev




Regimens containing oxaliplatin or irinotecan with/without bevacizumab










Regimens containing only 5-FU with/without bevacizumab
Kabinnavar 2003 [47] 104 Randomized, multicenter,
phase III
mCRC, ECOG PS 0–1,
≥ 18 years
5-FU/LV TTP and ORR
5-FU/LV/Bev (5 mg/kg)
5-FU/LV/Bev (10 mg/kg)
Kabinnavar 2005 [48] 209 Randomized, multicenter,
phase III
mCRC, ECOG PS 1–2,
≥ 65 years
5-FU/LV/Bev (5 mg/kg) OS
5-FU/LV/placebo
Regimens containing only capecitabine with/without bevacizumab
Tebutt 2010 [40] (MAX) 313a Randomized, multicenter,
phase III






Cunningham 2013 [22] (AVEX) 280 Randomized, multicenter,
phase III







Hurwitz 2004/2005 [14, 42] - (AVF 2107)
IFL/Placebo: 5-FU: 500 mg/m2, bolus + LV: 20 mg/m2, during 2 h + irinotecan: 125 mg/m2, once/week for 4 weeks every 6 weeks.
IFL/Bev: same chemotherapy regimen + bevacizumab: 5 mg/kg intravenously every 15 days until progression.
Guan 2011 [24] - (ARTIST)
IFL/Placebo: 5-FU: 500 mg/m2 + LV: 20 mg/m2 (infusion: 6–8 h) + irinotecan: 125 mg/m2, once/week for 4 weeks every 6 weeks.
IFL/Bev: same chemotherapy regimen + bevacizumab: 5 mg/kg intravenously every 15 days until progression.
Stathopoulos 2010 [44]
IFL: 5-FU: 500 mg/m2 + LV: 200 mg/m2 + irinotecan: 135 mg/m2, in Day 1 (D1) every 3 weeks.
IFL/Bev: same chemotherapy regimen + bevacizumab: 7.5 mg/kg intravenously every 3 weeks until progression.
Saltz/Cassidy 2008/2011 [45, 46] - (NO16966)
FOLFOX/placebo: LV: 200 mg/m2/day intravenously in 2 h + 5-FU: 400 mg/m2/day in bolus, followed by 600 mg/m2/day in 22 h in Days 1
and 2 + oxaliplatin: 85 mg/m2, in 2 h, in D1;
FOLFOX/Bev: same chemotherapy regimen + bevacizumab: 5 mg/kg, Day 1; every 15 days;
XELOX/placebo: capecitabine: 1000 mg/m2 orally, twice/day, for 14 days + oxaliplatin: 130 mg/m2 intravenously in D1;
XELOX/Bev: same chemotherapy regimen + bevacizumab: 7.5 mg/kg in D1; every 21 days, until progression.
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were also higher in the group treated with bevacizumab
(Table 3).
Patients tolerated well the association of bevacizumab
and IFL. The proportion of adverse events (grade ≥ 3)
was comparable between groups (IFL: 61 % vs. IFL +
bevacizumab: 69 %).
Stathopoulos et al. trial
This study [44] analyzed 222 patients with mCRC and
measurable disease. The trial randomized 144 patients
to receive bevacizumab (7.5 mg/kg) plus chemotherapy
(IFL regimen) every 3 weeks and 108 patients to receive
IFL alone. The primary endpoint was overall survival.
Treatment continued until progression of disease
(Table 2).
Response rate was similar between groups (IFL + beva-
cizumab: 36.8 % vs. IFL: 35.2 %; p = NS). Overall survival
was also similar between groups (IFL + bevacizumab:
IFL: 22 months vs. 25 months; p = 0.1391) (Table 3).
In this trial, the authors reported only the overall ad-
verse events (without stratifying by degree). Hematologic
toxicities were similar between groups (leukopenia, IFL
+ bevacizumab: 34.2 % vs. IFL: 36.1 %; anemia, IFL +
bevacizumab: 31.6 % vs. IFL: 33.3 %; thrombocytopenia,
IFL + bevacizumab: 3.5 % vs. IFL: 4.6 %). Regarding non-
hematological toxicities, four adverse events were more
frequent in patients treated with IFL + bevacizumab than
with IFL alone (hypertension: 20.2 % vs. 0 %; proteinuria:
6.1 % vs. 0 %; bleeding: 2.6 % vs. 0 %; and gastrointes-
tinal perforation: 0.9 % vs. 0 %). Rates of nausea, vomit-
ing and diarrhea were similar between the groups.
Studies containing chemotherapy (oxaliplatin-based) +
bevacizumab
One randomized trial analyzed the combination of beva-
cizumab with oxaliplatin-based regimens in the therapy
of previously untreated mCRC [45, 46].
NO16966 trial
This multicenter study [46] associated bevacizumab with
2 chemotherapy regimens (FOLFOX or XELOX) in pa-
tients with mCRC. In the bevacizumab + FOLFOX com-
bination, patients received bevacizumab (5 mg/kg) on
day 1 of chemotherapy every 15 days. In bevacizumab +
XELOX combination, patients received bevacizumab
(7.5 mg/kg) on day 1 of chemotherapy every 21 days.
The trial randomized 701 patients to receive XELOX/
FOLFOX + bevacizumab and 699 patients to receive
XELOX/FOLFOX + placebo (Table 2).
Table 2 Characteristics of randomized studies evaluating bevacizumab plus chemotherapy in patients with mCRC in first line
chemotherapy (Continued)
Passardi 2013/2015 [21, 23] - (ITACA)
FOLFOX: LV: 100 mg/m2/day intravenously D1 and D2 + 5-FU: 400 mg/m2/day in bolus D1 and D2, followed by 600 mg/m2 in 22 h in Days 1
and 2 + oxaliplatin: 85 mg/m2, in 2 h, in D1;
FOLFIRI: LV: 100 mg/m2/day intravenously D1 and D2 + 5-FU: 400 mg/m2/day in bolus D1 and D2, followed by 600 mg/m2 in 22 h in Days 1
and 2 + irinotecan 180 mg/m2, in D1;
FOLFOX or FOLFIRI/Bev: same chemotherapy regimen + bevacizumab: 5 mg/kg, Day 1; every 15 day;
Kabinnavar 2003 [47]
5-FU/LV: 5-FU: 500 mg/m2/LV: 500 mg/m2, weekly for 6 weeks every 8 weeks.
5-FU/LV/Bev (5 mg/kg): same chemotherapy regimen + bevacizumab: 5 mg/kg, Day 1, every 15 day;
5-FU/LV/Bev (10 mg/kg): same chemotherapy regimen + bevacizumab: 10 mg/kg, Day 1, every 15 day;
Kabinnavar 2005 [48]
5-FU/LV: 5-FU: 500 mg/m2/LV: 500 mg/m2, weekly for 6 weeks every 8 weeks + placebo every 15 day.
5-FU/LV/Bev (5 mg/kg): same chemotherapy regimen + bevacizumab: 5 mg/kg, Day 1, every 15 day;
Tebutt 2010 [40] (MAX)a
Capecitabine: 1000–1250 mg/m2 orally, twice/day, for 14 days;
Capecitabine/Bev: same chemotherapy regimen + bevacizumab: 7.5 mg/kg D1; every 21 days, until progression.
Cunningham 2013 [22] - (AVEX)
Capecitabine: 1000 mg/m2 orally, twice/day, for 14 days;
Capecitabine/Bev: same chemotherapy regimen + bevacizumab: 7.5 mg/kg D1; every 21 days, until progression.
Abbreviations: mCRC metastatic colorectal cancer, Bev bevacizumab, IFL fluorouracil/leucovorin + irinotecan, 5-FU fluorouracil, LV leucovorin, OS overall survival, PFS
progression-free survival, FOLFOX bolus and infusional fluorouracil/leucovorin + oxaliplatin, XELOX oxaliplatin + capecitabine, ECOG Eastern Cooperative Oncology
Group, PS performance status, TTP time to progression, ORR overall response rate
aExcluded patients with mitomycin; bFOLFOX4 was used in 60 % of the patients and FOLFIRI in 40 %
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Overall response rate was similar between groups
(XELOX/FOLFOX + bevacizumab: 47 % vs. XELOX/
FOLFOX + placebo: 49 %; p = 0.31) and progression-free
survival was higher in the group treated with XELOX/
FOLFOX + bevacizumab (9.4 months vs. 8.0 months; p
= 0.0023). Overall survival was also similar between
groups (XELOX/FOLFOX + bevacizumab: 21.3 months
vs. XELOX/FOLFOX + placebo: 19.9 months; p = 0.0769)
(Table 3).
Hematologic toxicities were not reported. Non-
hematological toxicities (grade ≥ 3) were generally 5 %
higher in patients treated with XELOX/FOLFOX +




Comparison Response rate PFS OS
HR (95 % CI) HR (95 % CI)
Regimens containing irinotecan with/without bevacizumab
Hurwitz 2004/2005 [14, 42]
(AVF 2107)
402 IFL/Bev 44.8 % 10.6 months 20.3 months
411 IFL/placebo 34.8 % 6.2 months 15.6 months
p = 0.004 HR: 0.54 (0.37–0.78) HR: 0.66 (0.52–0.85)
Guan 2011 [24] (ARTIST) 139 IFL/Bev 35.3 % 8.3 months 18.7 months
64 IFL 17.2 % 4.2 months 13.4 months
p = 0.013 HR: 0.44 (0.31–0.63) HR: 0.62 (0.41–0.95)
Stathopoulos 2010 [44] 114 IFL/Bev 36.8 % NR 22 months
108 IFL 35.2 % 25 months
p = NS HR: 1.05 (0.81–1.36)b
Regimens containing oxaliplatin with/without bevacizumab
Saltz/Cassidy 2008/2011 [45, 46]
(NO16966)
699 XELOX or FOLFOX/Bev 47 % 9.4 months 21.3 months
701 XELOX or FOLFOX/placebo 49 % 8.0 months 19.9 months
p = 0.31 HR: 0.83 (0.72–0.95)a HR: 0.89 (0.76–1.03)
Regimens containing oxaliplatin or irinotecan with/without bevacizumab
Passardi 2013/2015 [21, 23]
(ITACA)c
176 FOLFOX or FOLFIRI/Bev 50.6 % 9.6 months 20.8 months
194 FOLFOX or FOLFIRI 50 % 8.4 months 21.3 months
p = 0.865 HR: 0.86 (0.70-1.07) HR: 1.13 (0.89-1.43)
Regimens containing only 5-FU with/without bevacizumab
Kabinnavar 2003 [47]
(AVF0780)
35 5-FU/LV/Bev (5 mg/kg) 40 % 9.0 months 21.5 months
33 5-FU/LV/Bev (10 mg/kg) 24 % 7.2 months 16.1 months
36 5-FU/LV 17 % 5.2 months 13.8 months
(p = 0.08) HR: 0.54 (0.33–0.88) HR: NR
Kabinnavar 2005 [48]
(AVF2192)
104 5-FU/LV/Bev 26 % 9.2 months 16.6 months
105 5-FU/LV 15.2 % 5.5 months 12.9 months
p = 0.055 HR: 0.50 (0.35–0.73) HR: 0.79 (0.56–1.10)
Regimens containing only capecitabine with/without bevacizumab
Tebutt 2010 [40] (MAX) 157 Capecitabine/Bev 38.1 % 8.5 months NR
156 Capecitabine 30.3 % 5.7 months
p = 0.16 HR: 0.63 (0.50–0.79) HR: 0.88 (0.68–1.13)
Cunningham 2013 [22] (AVEX) 140 Capecitabine/Bev 19 % 9.1 months 20.7 months
140 Capecitabine 10 % 5.1 months 16.8 months
p = 0.04 HR: 0.53 (0.41–0.69) HR: 0.79 (0.57–1.09)
Abbreviations: mCRC metastatic colorectal cancer, Bev bevacizumab, IFL fluorouracil/leucovorin + irinotecan, 5-FU fluorouracil, LV leucovorin, OS overall survival, PFS
progression-free survival, FOLFOX bolus and infusional fluorouracil/leucovorin + oxaliplatin, XELOX oxaliplatin + capecitabine, ITT intent to treat, NR not reported, HR
hazard ratio, CI confidence interval, NS not significant
a97.5 % IC; bcalculated by the method of Parmar; cFOLFOX4 was used in 60 % of the patients and FOLFIRI in 40 %
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bevacizumab compared with XELOX/FOLFOX +
placebo.
Studies containing chemotherapy (irinotecan or
oxaliplatin-based) + bevacizumab
ITACA trial
This multicenter study [21] was presented at ASCO in
2013 and published in full afterwards [23]. A total of 370
(ITT) mCRC patients were randomized to receive first-
line chemotherapy (FOLFOX4 or FOLFIRI) plus bevaci-
zumab (5 mg/kg) or chemotherapy alone. The primary
endpoint was progression-free survival. FOLFOX4 regi-
men was used by 60 % of the patients and FOLFIRI by
40 %. Results showed no statistically significant differ-
ences in progression-free survival, overall survival and
overall response rate (Table 3). Hematologic toxicities
were similar between the groups. Regarding non-
hematological toxicities, five adverse events were more
frequently found in patients treated with chemotherapy
+ bevacizumab than with chemotherapy alone (hyper-
tension: 27.8 % vs. 10.8 %; fatigue: 10.3 % vs. 3.1 %; pro-
teinuria: 22.2 % vs. 13.4 %; bleeding: 17.0 % vs. 4.6 %;
and thrombosis: 21 % vs. 12.9 %). Rates of nausea,
vomiting and diarrhea were similar between the groups.
Studies containing chemotherapy (only 5-FU) +
bevacizumab
Two randomized studies investigated the use of bevacizu-
mab with chemotherapy containing only 5-FU [47, 48].
AVF0780 trial
This randomized study [47] evaluated the use of bevaci-
zumab combined with chemotherapy (“Roswell Park”
scheme) in 104 patients with mCRC. Patients were ran-
domly assigned to one of three treatment groups: 36 to
receive chemotherapy alone, 35 to receive chemotherapy
plus low-dose bevacizumab (5 mg/kg every 2 weeks),
and 33 to receive chemotherapy plus high-dose bevaci-
zumab (10 mg/kg every 2 weeks) (Table 2).
The group treated with bevacizumab presented better
overall response rate (control arm: 17 %; low-dose arm:
40 %; high-dose arm: 24 %), longer time to disease pro-
gression (control arm: 5.2 months; low-dose arm:
9.0 months; high-dose arm: 7.2 months) and longer
overall survival (control arm: 13.8 months; low-dose
arm: 21.5 months; high-dose arm: 16.1 months)
(Table 3). Toxicity profiles are described in Tables 4
and 5. The study did not report the degree of protein-
uria, however none of the patients developed nephrotic
syndrome.
AVF2192 trial
This study [48] randomized patients to receive chemo-
therapy (“Roswell Park” scheme) plus placebo (n = 105)
or chemotherapy plus bevacizumab (n = 104). The pri-
mary endpoint was overall survival. The trial included
patients (aged ≥65 years) who were not optimal candi-
dates for treatment with irinotecan [41] (Table 2).
The addition of bevacizumab to chemotherapy in-
creased the overall response rate (5-FU + leucovorin +
bevacizumab: 26.0 % vs. 5-FU + leucovorin + placebo:
15.2 %; p = 0.055) and progression-free survival (5-FU
+ leucovorin + bevacizumab: 9.2 months vs. 5-FU + leu-
covorin + placebo: 5.5 months; p = 0.0002), but had no
difference in overall survival (5-FU + leucovorin + beva-
cizumab: 16.6 months vs. 5-FU + leucovorin + placebo:
12.9 months; p = 0:16) (Table 3).
Regarding adverse events, grade 3 hypertension was
more frequent in the bevacizumab arm (16 % vs. 3 %),
(Table 5).
Studies containing chemotherapy (capecitabine only) +
bevacizumab
Two randomized studies assessed bevacizumab plus
chemotherapy compared to capecitabine alone [22, 40].
MAX trial
This multicenter phase III trial evaluated bevacizumab
plus chemotherapy versus capecitabine alone [40]. The
trial analyzed patients with mCRC without prior
chemotherapy. Overall, 471 patients were randomly
assigned to receive capecitabine; capecitabine plus bev-
acizumab (7.5 mg/kg); or capecitabine plus bevacizu-
mab and mitomycin. The primary endpoint was
progression-free survival. Since the chemotherapy regi-
men including mitomycin is not considered standard
for mCRC according to the main international guide-
lines, that particular group was not evaluated in this
meta-analysis.
Overall response rate (capecitabine + bevacizumab:
56 % vs. 43 %; p = 0.16) and overall survival were similar
between groups (Table 3). Progression-free survival was
higher in the group treated with capecitabine + bevacizu-
mab (8.5 months vs. 5.7 months; p < 0.001).
Hand-foot syndrome (also known as palmar-plantar
erythrodysesthesia) and diarrhea were the most common
grades ≥3 toxicities (Table 5).
AVEX trial
This phase III trial [22] included patients (aged ≥ 70 years)
with previously untreated mCRC, who were not fit candi-
dates for oxaliplatin-based or irinotecan-based chemother-
apy regimens. Patients were randomly assigned to receive
bevacizumab plus capecitabine (n = 140) or capecitabine
alone (n = 140). The primary endpoint was progression-
free survival.
Chemotherapy plus bevacizumab achieved higher
overall response rate (19 % vs. 10 %; p = 0.04) and
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progression-free survival (9.1 months vs. 5.1 months;
p < 0.0001). Median overall survival was 20.7 months
in the combination arm and 16.8 months in the cape-
citabine alone group (p = 0.18) (Table 3).
The frequencies of grade ≥3 adverse events related to
chemotherapy, with the exception of hand-foot syn-
drome, remained similar between the groups as seen on
Tables 4 and 5.
Meta-analyses
The meta-analyses performed found that the combin-
ation of bevacizumab with chemotherapy resulted in
higher overall response rate, progression-free survival
and overall survival.
Overall response rate was higher in patients who re-
ceived chemotherapy plus bevacizumab (RR = 0.89;
95 % CI: 0.82 to 0.96; 0.003; NNT = 20). Nevertheless,
Table 4 Results of hematological adverse events (grade > 3) of the included studies that evaluated bevacizumab plus
chemotherapy in mCRC
n Anemia Neutropenia Febrile neutropenia Thrombocytopenia
Regimens containing irinotecan with/without bevacizumab
Hurwitz 2004/2005 [14, 42] (AVF 2107)
IFL/Bev 393 NR 37.0 % NR NR
IFL/placebo 397 31.1 %
Guan 2011 [24] (ARTIST)
IFL/Bev 141 4 % 33 % 2 % 3 %
IFL 70 1 % 19 % 2 % 4 %
Stathopoulos 2010 [44]
IFL/Bev 114 NR NR NR NR
IFL 108
Regimens containing oxaliplatin with/without bevacizumab
Saltz/Cassidy 2008/2011 [45, 46] (NO16966)
XELOX or FOLFOX/Bev 694 NR NR NR NR
XELOX or FOLFOX/placebo 675
Regimens containing oxaliplatin or irinotecan with/without bevacizumab
Passardi 2013/2015 [21, 23] (ITACA)
FOLFOX or FOLFIRI/Bev 176 1.1 % 39.6 % 0.6 % 2.3 %
FOLFOX or FOLFIRI 194 2.6 % 42.3 % 2.1 % 1.0 %
Regimens containing only 5-FU with/without bevacizumab
Kabinnavar 2003 [47] (AVF0780)
5-FU/LV/Bev (5 mg/kg) 35 NR 5.7 % NR NR
5-FU/LV/Bev (10 mg/kg) 32 3.1 %
5-FU/LV 35 2.85 %
Kabinnavar 2005 [48] (AVF2192)
5-FU/LV/Bev 100 NR 5 % NR NR
5-FU/LV 104 7 %
Regimens containing only capecitabine with/without bevacizumab
Tebutt 2010 [40] (MAX)
Capecitabine/Bev 157 NR 0 % 2.5 % 0 %
Capecitabine 156 1.3 % 1.9 % 0 %
Cunningham 2013 [22] (AVEX)
Capecitabine/Bev 134 NR 1 % NR NR
Capecitabine 136 1 %
Abbreviations: mCRC metastatic colorectal cancer, Bev bevacizumab, IFL fluorouracil/leucovorin + irinotecan, FOLFOX bolus and infusional fluorouracil/leucovorin +
oxaliplatin, XELOX oxaliplatin + capecitabine, NR not reported
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the results had significant heterogeneity (Chi2 = 23.57;
df = 8 [p = 0.003]; I2 = 66 %), (Fig. 2). We performed a
random-effects model analysis to better explore this
heterogeneity. In this analysis, this result remained fa-
vorable to the use of chemotherapy plus bevacizumab
(RR = 0.81; 95 % CI: 0.68 to 0.95; p = 0.01).
The progression-free survival was also higher in pa-
tients treated with chemotherapy plus bevacizumab (HR
= 0.69; 95 % CI: 0.63 to 0.75; p < 0.00001; NNT = 3),
again with significant heterogeneity (Chi2 = 27.5; df = 7
[p = 0.0003]; I2 = 75 %) and difference among the groups
(p < 0.0001; I2 = 84.6 %), (Fig. 3). In this case, we also
performed a random-effects model analysis, in which
results remained favorable to the use of chemotherapy
plus bevacizumab (HR = 0.61; 95 % CI: 0.51 to 0.74; p <
0.00001).
Table 5 Results of non-hematological adverse events (grade > 3) of the included studies that evaluated bevacizumab plus
chemotherapy in mCRC





Regimens containing irinotecan with/without bevacizumab
Hurwitz 2004/2005 [14, 42] (AVF 2107)
IFL/Bev 393 32.4 % 11.0 % 0.8 % 1.5 % NR 19.4 % 3.1 %
IFL/placebo 397 24.7 % 2.3 % 0.8 % 0 % 16.2 % 2.5 %
Guan 2011 [24] (ARTIST)
IFL/Bev 141 26 % 4 % 1 % 1 % 13 % 1 % 1 %
IFL 70 21 % 0 % 0 % 0 % 12 % 0 % 1 %
Stathopoulos 2010 [44]
IFL/Bev 114 NR NR NR NR NR NR NR
IFL 108
Regimens containing oxaliplatin with/without bevacizumab
Saltz/Cassidy 2008/2011 [45, 46] (NO16966)
XELOX or FOLFOX/Bev 694 NR 4 % <1 % <1 % NR 10 % 2 %
XELOX or FOLFOX/placebo 675 1 % 0 % <1 % 6 % 1 %
Regimens containing oxaliplatin or irinotecan with/without bevacizumab
Passardi 2013/2015 [21, 23] (ITACA)
FOLFOX or FOLFIRI/Bev 176 8.0 % 27.8 % 22.2 % NR 5.2 % 21 % 17.0 %
FOLFOX or FOLFIRI 194 5.7 % 10.8 % 13.4 % 3.7 % 12.9 % 4.6 %
Regimens containing only 5-FU with/without bevacizumab
Kabinnavar 2003 [47] (AVF0780)
5-FU/LV/Bev (5 mg/kg) 35 28.6 % 8.6 % NR NR NR 14.3 % 0 %
5-FU/LV/Bev (10 mg/kg) 32 31.2 % 25 % 6.2 % 9.3 %
5-FU/LV 35 37.1 % 0 % 2.8 % 0%a
Kabinnavar 2005 [48] (AVF2192)
5-FU/LV/Bev 100 39 % 16 % 1 % 2 % NR 18 % 5 %
5-FU/LV 104 40 % 3 % 0 % 0 % 18 % 3 %
Regimens containing only capecitabine with/without bevacizumab
Tebutt 2010 [40] (MAX)
Capecitabine/Bev 157 17 % 3.8 % 3.2 % 1.9 % 10.2 % 12.1 % 1.3 %
Capecitabine 156 11 % 0.6 % 0.6 % 0.6 % 10.9 % 7.1 % 2.6 %
Cunningham 2013 [22] (AVEX)
Capecitabine/Bev 134 7 % 2 % 1 % 0 % 3 % 11 % 0 %
Capecitabine 136 6 % 1 % 0 % 0 % 1 % 5 % 1 %
Abbreviations: mCRC metastatic colorectal cancer, Bev bevacizumab, IFL fluorouracil/leucovorin + irinotecan, FOLFOX bolus and infusional fluorouracil/leucovorin + oxaliplatin,
XELOX oxaliplatin + capecitabine, NR: not reported
aEpistaxis and bleeding were put together
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Lastly, overall survival was higher in patients who re-
ceived chemotherapy plus bevacizumab (HR = 0.87; 95 %
CI: 0.80 to 0.95; p = 0.002; NNT = 7). This result had
moderate heterogeneity (Chi2 = 15.08; df = 7 [p = 0.03];
I2 = 54 %), (Fig. 4). Analysis by random-effects model
found that differences in these endpoints remained in
favor of chemotherapy plus bevacizumab (HR = 0.86;
95 % CI: 0.75 to 0.98; p = 0.03) (Fig. 5).
As an additional attempt of exploring the heterogen-
eity found in survival analyses, we discarded two of the
studies that included patients with mean age over
70 years [22, 48], however the results still showed signifi-
cant heterogeneity. The same strategy was employed in
regards to the Eastern Cooperative Oncology Group per-
formance status (ECOG PS). When the study [48] in-
cluding only patients with ECOG PS 1–2 was taken out
of the analysis, heterogeneity remained present in the
survival outcomes results.
Regarding adverse events and severe toxicities (grade
≥3), the group receiving chemotherapy plus bevacizu-
mab had higher rates of hypertension (RR = 3.56 95 %
CI: 2.58 to 4.92; p < 0.00001; NNH = 17), proteinuria
(RR = 1.89; 95 % CI: 1.26 to 2.84; p = 0.002; NNH = 100),
gastrointestinal perforation (RR = 3.63; 95 % CI: 1.31 to
10.09; p = 0.01; NNH = 100), any thromboembolic events
(RR = 1.44; 95 % CI: 1.20 to 1.73; p = 0.0001; NNH = 25),
and bleeding (RR = 1.81; 95 % CI: 1.22 to 2.67; p = 0.003;
NNH = 50), without heterogeneity (Additional file 2 and
3: Figure S1 and S2).
According to the funnel plot analysis [35], the possibil-
ity of publication bias was low for all efficacy endpoints
(Additional file 4).
Fig. 2 Comparative effect in objective response rates of chemotherapy with bevacizumab versus chemotherapy alone.
Abbreviations: CT, chemotherapy
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Subgroup analysis
Type of fluoropyrimidine administration
In the assessment of efficacy, a subgroup analysis evalu-
ating type of administration demonstrated that the over-
all response rate was higher in patients treated with
bolus fluoropyrimidine plus bevacizumab (RR = 0.74;
95 % CI: 0.64 to 0.85; p < 0.0001; NNT = 10) with mod-
erate heterogeneity (Chi2 = 5.74; df = 4 [p = 0.22]; I2 =
30 %). Other subgroups treated with infusional chemo-
therapy or capecitabine-based regimens, both combined
with bevacizumab, showed no statistically significant dif-
ference (infusional 5-FU: RR = 0.96; 95 % CI: 0.84 to
1:08; p = 0.47; and capecitabine-based: RR = 0.92; 95 %
CI: 0.80 to 1.06; p = 0.25).
We performed a random-effects model analysis to bet-
ter explore this heterogeneity. In this analysis, results
remained favorable to the use of chemotherapy with
bolus fluoropyrimidine plus bevacizumab (RR = 0.73;
95 % CI: 0.59 to 0.90; p = 0.004).
The progression-free survival was also higher in pa-
tients receiving bolus 5-FU plus bevacizumab (HR =
0.50; 95 % CI: 0.41 to 0.60; p < 0.00001; NNT = 2), with
no heterogeneity (Chi2 = 0.76; df = 3 [p = 0.86]; I2 = 0 %)
and also capecitabine-based regimens plus bevacizumab
(HR = 0.66; 95 % CI: 0.58 to 0.75; p < 0.00001; NNT = 3),
although with significant heterogeneity (Chi2 = 5.22; df =
2 [p = 0.07]; I2 = 62 %). There was no significant differ-
ence in progression-free survival with infusional 5-FU
plus bevacizumab (HR = 0.88; 95 % CI: 0.76 to 1.01; p =
0.07).
In this instance, we also performed a random-effects
model analysis, in which results remained favorable in
the groups treated with bolus 5-FU plus bevacizumab
(HR = 0.50; 95 % CI: 0.41 to 0.60; p < 0.00001) or with
capecitabine-based regimens plus bevacizumab (HR =
0.64; 95 % CI: 0.52 to 0.80; p < 0.0001).
Overall survival had similar results to those seen for
progression-free survival, with statistically significant
difference for bolus 5-FU plus bevacizumab (HR =
0.78; 95 % CI: 0.68 to 0.91; p = 0.001; NNT = 4) with
significant heterogeneity (Chi2 = 8.11; df = 3 [p = 0.04];
I2 = 63 %) and capecitabine-based regimens plus
Fig. 3 Comparative effect in progression-free survival of chemotherapy with bevacizumab versus chemotherapy alone (Fixed-effect model analysis).
Abbreviations: CT, chemotherapy; CI, confidence interval
Botrel et al. BMC Cancer  (2016) 16:677 Page 12 of 19
bevacizumab (HR = 0.84; 95 % CI: 0.73 to 0.97; p = 0.02;
NNT = 6) without heterogeneity (Chi2 = 0.26; df = 2 [p =
0.88]; I2 = 0 %). There was no significant difference in
overall survival with infusional 5-FU plus bevacizumab
(HR = 1.03; 95 % CI: 0.87 to 1.21; p = 0.76).
Once more, the random-effects model analysis showed
that results remained favorable to the use of bolus 5-FU
plus bevacizumab (HR = 0.77; 95 % CI: 0.60 to 0.99; p =
0.05) or capecitabine-based regimens plus bevacizumab
(HR = 0.84; 95 % CI: 0.73 to 0.97; p = 0.02).
Type of cytotoxic agents
According to the type of systemic therapy, the overall re-
sponse rate was higher in the subgroup receiving a regi-
men containing irinotecan (IFL or FOLFIRI) plus
bevacizumab (RR = 0.82; 95 % CI: 0.71 to 0.94; p = 0.004;
NNT = 13), but with moderate heterogeneity (Chi2 =
8.33; df = 3 [p = 0.04]; I2 = 64 %) and monotherapy with
fluoropyrimidine plus bevacizumab (RR = 0.65; 95 % CI:
0.51 to 0.83; p = 0.0005; NNT = 10), with no heterogen-
eity (Chi2 = 2.06; df = 3 [p = 0.56]; I2 = 0 %). In subgroups
receiving oxaliplatin-containing regimens (XELOX or
FOLFOX) plus bevacizumab response rates were simi-
lar to those seen in the patients treated without bevaci-
zumab (RR = 1.02; 95 % CI: 0.92 to 1.13; p = 0.72) with
moderate heterogeneity (Chi2 = 1.35; df = 1 [p = 0.24];
I2 = 26 %).
We performed a random-effects model analysis to bet-
ter explore this heterogeneity. In this analysis, this result
remained favorable to the use of monotherapy with
fluoropyrimidine plus bevacizumab (RR = 0.66; 95 % CI:
0.52 to 0.84; p = 0.0009).
Progression-free survival was higher in subgroups
treated with irinotecan-containing regimens (IFL or
FOLFIRI) plus bevacizumab (HR = 0.57; 95 % CI:
0.47 to 0.70; p < 0.00001; NNT = 2), with heterogen-
eity (Chi2 = 4.86; df = 2 [p = 0.09]; I2 = 59 %). The
same was seen in patients treated with oxaliplatin-
containing regimen (XELOX or FOLFOX) plus
Fig. 4 Comparative effect in overall survival of chemotherapy with bevacizumab versus chemotherapy alone (Fixed-effect model analysis).
Abbreviations: CT, chemotherapy; CI, confidence interval
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bevacizumab (HR = 0.86; 95 % CI: 0.76 to 0.98; p =
0.02; NNT = 7), with moderate heterogeneity (Chi2 =
1.29; df = 1 [p = 0.26]; I2 = 23 %), and also in those
receiving fluoropyrimidine monotherapy plus bevaci-
zumab (HR = 0.56; 95 % CI: 0.49 to 0.65; p < 0.00001;
NNT = 2), without heterogeneity (Chi2 = 1.57; df = 3
[p = 0.67]; I2 = 0 %).
In a random-effects model analysis results remained
favorable to the use of irinotecan-containing chemother-
apy (IFL or FOLFIRI) plus bevacizumab (HR = 0.57;
95 % CI: 0.41 to 0.78; p = 0.0004) and fluoropyrimidine
monotherapy plus bevacizumab.
Regarding overall survival results, it was not possible to
include the ITACA trial [21, 23], since data by treatment
regimens (FOLFOX or FOLFIRI) were not reported.
Overall survival was higher for irinotecan-containing
regimens (IFL) plus bevacizumab (HR = 0.78; 95 % CI:
0.67 to 0.92; p = 0.003; NNT = 4), although with signifi-
cant heterogeneity (Chi2 = 8.11; df = 2 [p = 0.02]; I2 =
75 %), and for fluoropyrimidine monotherapy plus beva-
cizumab (HR = 0.83; 95 % CI: 0.70 to 0.99; p = 0.04;
NNT = 6), without heterogeneity (Chi2 = 0.36; df = 2 [p =
0.83]; I2 = 0 %).
KRAS status
We also explored if there were any interaction between
the KRAS status and the effect of treatment. In the sub-
group analysis of patients who received chemotherapy
plus bevacizumab we did not observed any difference in
response rates between patients with wild type or mu-
tated KRAS (WD: RR = 0.80; 95 % CI: 0.61 to 1.05; p =
0.11 and MT: RR = 0.99; 95 % CI: 0.65 to 1.51; p = 0.97).
The interaction test was negative for subgroup differ-
ences. The progression-free survival was higher in pa-
tients treated with chemotherapy plus bevacizumab
regardless of KRAS status (WD: HR = 0.71; 95 % CI: 0.60
to 0.85; p = 0.0002 and MT: HR = 0.70; 95 % CI: 0.54 to
0.90; p = 0.006). The interaction test was negative for
subgroup differences. Overall survival was similar be-
tween patients with wild type or mutated KRAS (WD:
HR = 0.79, CI95% = 0.58 to 1.07; p = 0.13 and MT: HR =
Fig. 5 Comparative effect in overall survival of chemotherapy with bevacizumab versus chemotherapy alone (random-effects model analysis).
Abbreviations: CT, chemotherapy; CI, confidence interval
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0.91, CI95% = 0.63 to 1.32; p = 0.62). The interaction test
was negative for subgroup differences.
Discussion
Several guidelines around the world consider the com-
bination of bevacizumab plus chemotherapy with 5-FU
plus oxaliplatin or irinotecan (FOLFOX, FOLFIRI, IFL,
XELOX, etc.) as an option for first-line treatment of
mCRC, especially in patients with mutated KRAS [1, 4,
49–60]. We found 9 systematic reviews with meta-
analysis evaluating the use of bevacizumab combined
with chemotherapy in the treatment of mCRC [16–20,
61–64].
The first review, published in 2009 [19], grouped pa-
tients treated with standard chemotherapy + bevacizu-
mab. This review included 5 studies [14, 46–48, 65], 4
in first-line and 1 in second-line treatment. Subgroup
analysis performed with patients treated with chemo-
therapy + bevacizumab in first-line demonstrated a
progression-free survival in favor of the group receiving
bevacizumab (HR: 0.61; 95 % CI: 0.45 to 0.83; p =
0.0017). There was also a difference in overall survival
favoring the group treated with bevacizumab (HR: 0.81;
95 % CI: 0.73 to 0.90; p = 0.00009).
Later, in 2010, another systematic review [16] corrobo-
rated the results of the previous publication including the
same 5 studies that evaluated standard chemotherapy +
bevacizumab [14, 46–48, 65]. Generally, progression-free
survival (HR = 0.63; 95 % CI: 0.49 to 0.81; p = 0.0004) and
overall survival (HR = 0.79; 95 % CI: 0.69 to 0.90; p =
0.0005) favored the group treated with bevacizumab.
In 2011, a new systematic review [17] included - in
addition to the 5 studies [14, 46–48, 65] described in
previous reviews [16, 19] - the results of another ran-
domized trial evaluating chemotherapy + bevacizumab in
mCRC first-line treatment [40]. Both progression-free
survival (HR = 0.62; 95 % CI: 0.52 to 0.74; p < 0.00001)
and overall survival (HR = 0.80; 95 % CI: 0.71 to 0.91; p
= 0.0004) favored chemotherapy with bevacizumab.
In 2012, Macedo et al. [18] conducted a systematic re-
view with meta-analysis focusing on the subgroups of
chemotherapies used in trials with bevacizumab. In this
review, 6 studies compared standard chemotherapy
alone versus chemotherapy plus bevacizumab in patients
with mCRC without prior treatment. This meta-analysis
concluded that bevacizumab was an effective agent for
mCRC first-line treatment. However, its effectiveness
was observed in specific types of chemotherapy such as
bolus fluorouracil, capecitabine-based regimens, and iri-
notecan containing schemes.
In 2013, Lv et al. [61] conducted a systematic review
with meta-analysis of 10 randomized trials including
most of the options of chemotherapy considered stand-
ard for mCRC. The overall analysis included patients in
first-line and second-line treatment for mCRC and also
those in adjuvant therapy. The overall result favored the
arms treated with bevacizumab regarding progression-
free survival (HR = 0.59; 95 % CI: 0.51 to 0.67) and over-
all survival (HR = 0.78; 95 % CI: 0.70 to 0.87).
All systematic reviews with meta-analysis published
until 2013 presented progression-free survival and over-
all survival results that favored the chemotherapy plus
bevacizumab combination, despite heterogeneity among
subgroups.
However, in 2014, other publication [20] showed that
the addition of bevacizumab to first-line chemotherapy
did not add clinical benefit for overall survival. This
meta-analysis included 7 studies and raised questions
about the real benefit of chemotherapy plus bevacizu-
mab combination in first-line therapy.
Three meta-analyses evaluating the impact of the
addition of bevacizumab to chemotherapy in patients
with CRC were published in 2015 [62–64].
The first, by Zhang et al. [64] included 9 studies, either
randomized-controlled trials or cohorts that assessed
bevacizumab plus standard chemotherapy in patients
with mCRC in first-line treatment. The author did not
perform subgroup analyses by mode of administration of
type of cytotoxic drug in combination with bevacizumab.
In general, results were favorable to the addition of bev-
acizumab regarding overall response rate (OR = 1.57,
95 % CI: 1.17 to 2.11, p = 0.003), progression-free sur-
vival (HR = 0.56, 95 % CI: 0.46 to 0.69, p < 0.00001) and
overall survival (HR = 0.83, 95 % CI: 0.76 to 0.91, p <
0.0001).
The second meta-analysis, by CY, et al. [63], included
10 studies on the use of bevacizumab in patients with
CRC. Similar to Lv et al. [61], the overall analysis in-
cluded patients in first-line and second-line treatment
for mCRC and also those in adjuvant therapy. Moreover,
there were no subgroup analyses regarding the impact of
treatment in each line of therapy or type of cytotoxic
drug. The overall result favored the arms treated with
bevacizumab regarding progression-free survival (HR =
0.61; 95 % CI: 0.53 to 0.71) and overall survival (HR =
0.84; 95 % CI: 0.74 to 0.96).
The third meta-analysis, by Hu et al. [62], included 7
trials on the addition of bevacizumab to standard
chemotherapy for patients with mCRC in first-line of
treatment. Overall response rates were higher for those
treated with bevacizumab (RR = 1.17, 95 % CI: 1.06 to
1.28, p = 0.001), as were progression-free survival (HR =
0.67, 95 % CI: 0.61 to 0.72) and overall survival (HR =
0.67, 95 % CI: 0.61 to 0.72).
Our review included the results of 3 studies [21–24]
that also evaluated the addition of bevacizumab to
first-line treatment of mCRC, which were not included
in any the previously published meta-analyses. Our
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results demonstrated that the overall response rate,
progression-free survival and overall survival were
higher in patients who received the combination of
chemotherapy plus bevacizumab in a fixed effects
model analysis, but with heterogeneity. These results
remain favorable to the same combination with beva-
cizumab, even after a random-effects model analysis
was performed.
One hypothesis that may explain the heterogeneity
found in this and other systematic reviews is the difference
in bevacizumab doses and individual inclusion criteria –
as age and ECOG PS of patients – for each study.
The wide range regarding mean age of patients detected
on the included trials might have contributed to the het-
erogeneity seen in all meta-analyses performed to this
date. Two trials included patients with mean age between
50 and 60 years [14, 24, 42]; four had patients with mean
age between 60 and 70 years [21, 23, 40, 44–46] and two
included patients with mean age over 70 years [22, 48].
Levels of ECOG performance status of included pa-
tients were also distinct along the trials, varying from PS
0–1 [14, 24, 42, 45–47]; PS 0–2 [21–23, 40, 44] and PS
1–2 [48].
The mode of chemotherapy administration and type of
cytotoxic drug also seemed to influence the results, since
in the subgroups analysis the response rate was higher
in patients who received bolus fluoropyrimidine plus
bevacizumab and in those treated with irinotecan-
containing regimens or fluoropyrimidine monotherapy
plus bevacizumab.
Progression-free survival and the overall survival were
also influenced by the same variables, as better results were
seen in patients receiving bolus 5-FU or capecitabine-based
chemotherapy plus bevacizumab. Regarding the type of
cytotoxic regimen, all subgroups (irinotecan-containing,
oxaliplatin-containing and fluoropyrimidine monother-
apy) had favorable results on progression-free survival
with the addition of bevacizumab. However, only pa-
tients treated with irinotecan-containing regimens (IFL)
or fluoropyrimidine monotherapy had statistically sig-
nificant results in overall survival with the association
of bevacizumab.
Oxaliplatin might not be an ideal partner for bevaci-
zumab, as pointed out by Macedo et al. [18]. Both
studies that combined oxaliplatin-based chemotherapy
[21, 23, 45, 46] plus bevacizumab failed to show bene-
fit in overall survival. In the trial by Passardi [21, 23]
FOLFOX4 was used in 60 % of the patients. Separate
data on overall survival FOLFIRI or FOLFOX were not
reported, however. The bevacizumab dose in studies
using oxaliplatin-based chemotherapy was similar to
those seen in studies with irinotecan regimens. Also,
the ECOG PS of patients was comparable to that seen
in irinotecan-based or 5FU monotherapy regimens.
The efficacy results of our meta-analysis were similar
to those found by Macedo et al. [18], who also assessed
the addition of bevacizumab in different settings, albeit
with fewer studies included. To our knowledge, ours is
the only meta-analysis that evaluated subgroups of pa-
tients by type of cytotoxic treatment and mode of
administration.
This systematic review is comprised by trials published
through a span of more than 10 years. This opens issues
regarding the appropriateness of pooling the results of
older trials from the standpoint of current standards of
care in advanced colorectal cancer. Sensitivity analyses
were performed excluding AVF 2107 [14, 42] and
Kabinnavar et al. [47, 48] trials, both with patient ac-
crual taking place in the early 2000s (data not shown).
Although overall survival data didn’t statistically favor
bevacizumab-containing regimens (HR = 0.92; 95 % CI
0.83, 1.01), benefits in PFS persisted in the same magni-
tude as observed in the main analysis (HR = 0.72; 95 %
CI 0.66, 0.79). It should be noted that this exploratory
analysis carries some potential biases: Most trials in-
cluded were conducted with sample calculation taking
into account that the primary endpoint was PFS, limit-
ing the chance for identification of an overall survival
benefit even if this was a true effect of bevacizumab
containing regimens. Furthermore, crossover to bevaci-
zumab was not allowed in some trials [14, 42, 48] but it
did occur in others [22, 46, 47], while some studies did
not explicitly report such information [24, 40, 44].
Nevertheless, PFS lengthening have been shown to
strongly correlate with improvements in overall survival
in advanced colorectal cancer [66, 67].
Since bevacizumab is an antibody against VEGF, an-
other aspect that needs further clarification is the poten-
tial benefit of VEGF-A isoform plasma levels in patients
who are eligible for this targeted therapy. It is known
that VEGF is overexpressed in various human malignan-
cies [68] and it is considered to be an important regula-
tor of physiologic and pathologic angiogenesis [44, 69].
In many instances, VEGF is correlated with an adverse
prognosis (increased risk of tumor recurrence and me-
tastasis and decreased survival) [48]. Recently, a system-
atic review with meta-analysis presented at the ESMO
Meeting [70] explored this correlation and, despite the
small number of included studies, showed that VEGF-A
plasma levels seemed to predict benefit with bevacizu-
mab in early and advanced breast cancer. Appraisal of
VEGF-A levels in patients with mCRC might similarly
help to select those with the greatest potential for treat-
ment response.
None of the meta-analyses evaluating the addition of
bevacizumab to standard chemotherapy in patients with
mCRC was able to identify the potential benefit of
VEGF-A isoform plasma levels, or other efficacy
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biomarkers, since the included studies did not report
on that outcome. KRAS gene mutation status was not
predictive of bevacizumab outcome in patients with
mCRC. Efficacy results of chemotherapy alone versus
chemotherapy plus bevacizumab did not differ in re-
gard to biomarker status.
Regarding adverse events and severe toxicities (grade
≥ 3), the group receiving chemotherapy plus bevacizu-
mab had higher rates of hypertension, proteinuria,
gastrointestinal perforation and any thromboembolic
events.
This profile of toxicity warrants a greater level of atten-
tion to those patients at an increased risk for thrombo-
embolic events and gastrointestinal perforation (such as
the elderly or debilitated patients with Speritoneal carcin-
omatosis). As seen in another systematic review with
meta-analysis evaluating the use of bevacizumab plus
chemotherapy in lung cancer [71], hypertension and pro-
teinuria are usually controllable events and do not require
permanent discontinuation of therapy.
Conclusion
The combination of chemotherapy plus bevacizumab in-
creased the response rate, progression-free survival and
overall survival of previously untreated patients diag-
nosed with mCRC.
Regarding the mode of fluoropyrimidine administra-
tion, both bolus (IFL) and capecitabine-based regimens
combined with bevacizumab presented better results in
survival outcomes. As for the type of systemic therapy
associated with bevacizumab, regimens containing irino-
tecan and therapy with fluoropyrimidine monotherapy
showed better efficacy results. Thus, patients who are
not candidates for oxaliplatin-based or irinotecan-based
chemotherapy regimens may benefit from the treatment
with bevacizumab plus fluoropyrimidine monotherapy
regimen.
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